Welcome to our dedicated page for Nanobiotix S.A. American Depositary Shares news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. American Depositary Shares stock.
Nanobiotix S.A. (Euronext: NANO / ISIN: FR0011341205) is a leading clinical-stage nanomedicine company specializing in the development of groundbreaking approaches for cancer treatment. The company's core technology, NanoXray, augments the effectiveness of radiotherapy, offering a more efficient treatment option for cancer patients. The innovative NanoXray products are designed to be compatible with existing radiotherapy treatments and aim to treat a broad spectrum of solid tumors, such as soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma.
The primary product candidate, NBTXR3, is currently undergoing evaluation for its efficacy in treating soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers (both primary and metastases). Additionally, Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer in the Asia Pacific region.
Nanobiotix has also embarked on a preclinical research program in immuno-oncology, further expanding its portfolio and potential for transformative cancer therapies. NBTXR3 works by magnifying the effects of radiotherapy within tumor cells, thereby enhancing cancer treatment without increasing the dose to surrounding healthy tissues.
Recently, Nanobiotix has been focused on validating the safety and efficacy of RT-activated NBTXR3 by moving to global registration for LA-HNSCC, accounting for the majority of its operational and financial resources. The company plans to provide an updated global development plan for NBTXR3 after further alignment with the Joint Steering Committee (JSC).
In terms of financial performance, Nanobiotix has laid out a cautious strategy, ensuring that it remains well-funded to support ongoing and future operations. Their forward-looking statements highlight the potential risks and uncertainties that could affect their business and financial performance.
For the latest updates, Nanobiotix has scheduled a conference call and webcast on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST. It continues to engage the market, providing transparency to shareholders through various media and regular updates on their progress and milestones.
To keep up with the latest news, visit www.nanobiotix.com.
Nanobiotix provided an operational and financial update, highlighting significant clinical advancements for its lead candidate, NBTXR3. In the Expansion Study 102 involving high-risk, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) patients, the median overall survival reached 23 months. The company reported €83.9 million in cash as of December 31, 2021, down from €119.2 million in 2020. Revenue for 2021 was only €9.7k compared to €50.0k in 2020. Despite a net loss of €47.0 million, Nanobiotix is advancing multiple pivotal studies in 2022.
Nanobiotix (NASDAQ: NBTX, Euronext: NANO) will report its full-year financial results for December 31, 2021, on March 30, 2022, after market close. The announcement will precede a conference call on March 31, 2022, at 8:00 AM EDT, led by CEO Laurent Levy and CFO Bart Van Rhijn. Investors can submit questions ahead of time via email. The company is advancing its lead oncology product, NBTXR3, currently in clinical trials for head and neck cancer, with strategic collaborations for further development in various cancer types and therapies.
Nanobiotix announced its total outstanding shares as of
Nanobiotix reported the outstanding shares and voting rights as of January 31, 2021. The company has 34,825,872 shares outstanding, with 36,003,389 total voting rights gross and 35,990,682 total voting rights net. This disclosure complies with the French Commercial Code and the regulations of the French Financial Markets Authority.
Nanobiotix operates in innovative oncology, with its lead product NBTXR3 authorized in Europe for soft tissue sarcoma. The company is listed on both Euronext Paris and NASDAQ under the ticker NBTX.
Nanobiotix has announced a peer-reviewed clinical case study published in Clinical and Translational Radiation Oncology regarding its first-in-human treatment of NBTXR3 for unresectable pancreatic cancer. The study shows the feasibility of local endoscopic delivery with no treatment-related toxicity. Supported by MD Anderson Cancer Center, this phase I trial aims to assess the safety and establish a recommended phase II dose for future efficacy evaluation. The treatment may address unmet needs in managing locally advanced pancreatic cancer.
Nanobiotix announced the publication of new preclinical data for NBTXR3, which shows significant anti-tumor effects in an anti-PD-1 resistant lung cancer model. The study revealed that adding NBTXR3 to a combination of radiotherapy, anti-PD-1, and anti-CTLA-4 improved mouse survival rates from 0% to 50%. Notably, no re-challenged mice developed tumors, indicating a long-term anti-tumor immune memory. The data suggests the potential for further investigations of NBTXR3's immune priming effects in both preclinical and clinical settings.
Nanobiotix (Euronext: NANO, NASDAQ: NBTX) published its regulatory announcement as of December 31, 2021. The report states that there are 34,825,872 outstanding shares and 36,003,389 total voting rights gross. The net voting rights amount to 35,987,933. The figures are in compliance with French Commercial Code and the regulations of the French Financial Markets Authority. The company is developing its lead product candidate, NBTXR3, aiming to transform oncology treatment outcomes.
Nanobiotix has provided a corporate update, highlighting significant advancements with NBTXR3 for treating head and neck cancer. The first European patient has been randomized in the pivotal NANORAY-312 study, with U.S. and Asia site activations expected to follow. The company aims to establish a registration pathway for NBTXR3 in combination with anti-PD-1 therapy based on positive initial data from ongoing studies. Financially, Nanobiotix has extended its operating runway into Q2 2023 through improved operational efficiencies and capital optimization.
Nanobiotix announced the first patient enrollment in the pivotal NANORAY-312 phase III study assessing radiotherapy-activated NBTXR3, with or without cetuximab, for elderly patients with locally advanced head and neck squamous cell carcinoma. This study aims to prove the superiority of NBTXR3 over standard treatments. The US FDA has granted Fast Track designation for NBTXR3 in this patient group, allowing for faster review and potential accelerated approval.
Nanobiotix, a late-stage clinical biotechnology company, announced participation in three virtual investor conferences in
- Oddo BHF Forum 2022: January 6-11, 2022
- H.C. Wainwright Bioconnect Conference: January 10-13, 2022
- Biotech Showcase™ 2022: January 17-19, 2022
FAQ
What is the current stock price of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is the market cap of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is Nanobiotix S.A. known for?
What is NanoXray technology?
What types of cancer does NBTXR3 target?
Who is Nanobiotix partnered with in the Asia Pacific region?
What recent projects are Nanobiotix involved in?
When is the next conference call and webcast scheduled?
How does NBTXR3 enhance radiotherapy?
What is the significance of Nanobiotix’s preclinical research program?
Where can I find more information about Nanobiotix?
